{"id":380952,"date":"2020-11-13T10:43:28","date_gmt":"2020-11-13T15:43:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380952"},"modified":"2020-11-13T10:43:28","modified_gmt":"2020-11-13T15:43:28","slug":"apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/","title":{"rendered":"Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <em>Verana Health a<\/em><br \/>\n          <em>nalysis of American Academy of Ophthalmology IRIS<\/em><br \/>\n          <sup><br \/>\n            <em>\u00ae<\/em><br \/>\n          <\/sup><br \/>\n          <em> Registry presented in a late-breaking oral session <\/em><\/p>\n<\/li>\n<li>\n          <em>Real-world clinical data show significant disease progression over a two-year period in more than 69,000 patients with GA, highlighting the urgent need for treatment<\/em><\/p>\n<\/li>\n<li>\n          <em>Patients were nearly three times more likely to develop<\/em><br \/>\n          <em> new onset\u00a0<\/em><br \/>\n          <em>wet<\/em><br \/>\n          <em> age-related macular degeneration<\/em><br \/>\n          <em>(<\/em><br \/>\n          <em>AMD<\/em><br \/>\n          <em>)<\/em><br \/>\n          <em> in an eye with GA when wet AMD had already been detected in the <\/em><br \/>\n          <em>contralateral<\/em><br \/>\n          <em> eye<\/em><br \/>\n          \n        <\/li>\n<\/ul>\n<p>WALTHAM, Mass., Nov.  13, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=D7p3NtwLXD-KJKugUvHlp29XVZMRbYpBpznQ6AngbH7xehhj76wZczr0gEUNcekxQ7lPI6khcgkLPTrY4KcDed4cEL-WhkETgkGaml8UEqc=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>Apellis Pharmaceuticals<\/u><\/a>, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced findings from the largest retrospective database study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The analysis of the American Academy of Ophthalmology (AAO) IRIS<sup>\u00ae<\/sup> (Intelligent Research in Sight) Registry, the nation&#8217;s first comprehensive clinical registry for eye disease, was conducted in partnership with <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HYcd4wENFlh5iL6TLVqOlnBR_sbsSPvVxNsbU7lqaBh4GiZ4xMI279M2iS656CmvYu6ECJ9kmRYpcvLaiN3S3g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Verana Health<\/a>, the world\u2019s leading data analysis group in retinal diseases. The study highlights the significant impact of GA progression on vision, underscoring the high unmet need for GA treatment in clinical practice. The data were presented today in a late-breaking oral session as part of the Retina Subspecialty Day at AAO 2020 Virtual.<\/p>\n<p>The retrospective\u00a0study\u00a0included\u00a0more than 69,000\u00a0patients diagnosed with GA and analyzed\u00a0changes in\u00a0visual acuity and disease progression for over two years, as well as the occurrence of concurrent wet AMD.\u00a0GA is a complement-driven eye disease<sup>1,2<\/sup>\u202fthat can lead to significant vision loss and\u00a0affects approximately five million people\u00a0around the world.<sup>3,4<\/sup>\u202f\u00a0<\/p>\n<p>\u201cThere is no approved therapy for GA and with new agents under development, it is essential to have a detailed understanding of disease progression in real-world clinical practice,\u201d said Ehsan\u00a0Rahimy, M.D., lead study author and surgical\u00a0and\u00a0medical vitreoretinal specialist at the Palo Alto Medical Foundation. \u201cThe data show that GA patients at their first encounter have useful vision that may be preserved if an effective treatment were available. The progressive loss of visual acuity observed in this study over a two-year period underscores the urgent need for a therapy to slow disease progression.\u201d\u00a0<\/p>\n<p>Key findings from the real-world clinical data\u00a0show:\u00a0<\/p>\n<ul type=\"disc\">\n<li>Progression from GA to new onset wet AMD was observed in 4.7% of patients with bilateral GA (GA in both eyes) and 13.3% of patients with wet AMD in the contralateral eye during the first 12 months. The rate at 24 months was 8.2% and 21.6% in bilateral GA and wet AMD in the contralateral eye, respectively.\n<\/li>\n<li>At the first\u00a0study visit, patients\u00a0presented with relatively preserved vision,\u00a0especially in eyes with extrafoveal GA lesions (lesions outside the fovea, which is the central portion of the retina). However,\u00a0patients with extrafoveal\u00a0and foveal\u00a0GA\u00a0lesions\u00a0progressively lost vision\u00a0over time at a rate of approximately five letters per year.\u00a0\n<\/li>\n<li>A large proportion of GA patients\u00a0did\u00a0not return for a follow-up visit after two years.\u00a0Of the GA patients potentially eligible for inclusion in the analysis, only 40% had a follow-up visit\u00a0after\u00a0two\u00a0years and were ultimately included in the study. <\/li>\n<\/ul>\n<p>\u201cAs we work to develop the first potential\u00a0medicine for people with\u00a0GA, we are committed to\u00a0improving\u00a0understanding\u00a0of\u00a0the\u00a0disease. Our collaboration with Verana Health and the AAO IRIS<sup>\u00ae<\/sup>\u00a0Registry shows\u00a0that wet AMD is not a rare occurrence in GA patients, and there is an opportunity to preserve vision if new treatments become available,\u201d\u00a0said Federico Grossi, M.D., Ph.D., chief medical officer of Apellis.\u00a0\u201cThese results\u00a0highlight\u00a0the\u00a0significant\u00a0unmet need in GA, and we are working urgently to advance\u00a0pegcetacoplan, a targeted C3 therapy, in two\u00a0ongoing\u00a0Phase 3\u00a0GA\u00a0studies.\u201d\u00a0<\/p>\n<p>\n        <strong>About the IRIS<\/strong><br \/>\n        <sup><br \/>\n          <strong>\u00ae<\/strong><br \/>\n        <\/sup><br \/>\n        <strong>\u00a0Registry<\/strong><br \/>\n        <br \/>The American Academy of Ophthalmology IRIS<sup>\u00ae<\/sup>\u00a0(Intelligent Research in Sight) Registry is the nation&#8217;s first electronic health record-based comprehensive eye disease and condition registry. As of September 2020, the registry features over 59.99 million unique patients and includes 16,030 clinicians. It is a centralized data repository and reporting tool that can analyze patient data to produce easy-to-interpret national and inter-practice benchmark reports and provide scientific information to improve public health. The reports can validate the quality of care ophthalmologists provide and pinpoint opportunities for improvement.<\/p>\n<p>\n        <strong>About Verana Health<\/strong><br \/>\n        <br \/>Verana Health, Inc. partners with leading medical associations to transform clinical data into actionable real-world evidence. These partnerships enable Verana Health to harness the comprehensive data found in qualified clinical data registries and other specialty data sources to accelerate medical research and enhance patient care. Learn more at veranahealth.com.<\/p>\n<p>\n        <strong>About Geographic Atrophy (GA)<\/strong>\u202f\u00a0<br \/>GA is an advanced form of age-related macular degeneration (AMD), a leading cause of blindness. Excessive complement activation drives irreversible lesion growth in GA,<sup>5<\/sup>\u202fand C3 is the only target to precisely control complement overactivation.\u00a0Pegcetacoplan, studied in early and late-stage trials comprising a total of approximately 1,500 patients, is the only targeted C3 inhibitor being evaluated in late-stage trials to control lesion growth in GA.<sup>6<\/sup>\u00a0<\/p>\n<p>GA lesions affect the central portion of the retina, known as the macula, which is responsible for central vision. GA is progressive and irreversible, leading to central visual impairment and permanent loss of vision. Based on published studies, approximately one million people have GA in\u202fthe United States and five million people have GA globally.<sup>2,7<\/sup>\u202fThere are currently no\u202fapproved treatments for GA.\u00a0<\/p>\n<p>\n        <strong>About\u00a0Pegcetacoplan\u00a0(APL-2)<\/strong>\u202f\u00a0<br \/>Pegcetacoplan\u202fis an investigational, targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body\u2019s immune system, which can lead to the onset and progression of many serious diseases.\u202fPegcetacoplan\u202fis a synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b.\u202fApellis is evaluating\u202fpegcetacoplan\u202fin several clinical studies across hematology, ophthalmology, nephrology, and neurology.\u202fPegcetacoplan\u202fwas granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for\u202fthe treatment of paroxysmal nocturnal hemoglobinuria (PNH) and the treatment of geographic\u00a0atrophy, and\u00a0received orphan drug designation for the treatment of C3 glomerulopathy (C3G) by the FDA and European Medicines Agency. For additional information regarding our clinical trials,\u202fvisit\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oxUmz8llQ1oTIDce8W7mZs_6iis76bZ6B9R8o4pfIx1bKD35tI8bYC89K3Mew-yi4g8Xlq3PgsMrrtHYfXLWbDBsJK0QXFyBTpV5pHX4KrpDgb62Q3zqfUuvAOEQBlFy_etsvbZkoHwgkwqIgl2kPZ-6vDkhM2-nb6wwFHRPZLU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>https:\/\/apellis.com\/our-science\/clinical-trials<\/u><\/a>.\u00a0<\/p>\n<p>\n        <strong>About Apellis<\/strong>\u202f\u00a0<br \/>Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please\u202fvisit\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5_YAHt67DoVjaOf_PM8APT1Ze_Is2VhlH3SX5CKb8Nhy40wTFIWH7D5mdIVrdnzDqhq5kYZNAOZVUvekXrSIVg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>http:\/\/apellis.com<\/u><\/a>.\u00a0<\/p>\n<p>\n        <strong>Apellis Forward-Looking Statement<\/strong>\u00a0<br \/>Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute \u201cforward-looking statements\u201d within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the implications of preliminary clinical data. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether the company\u2019s clinical trials will be fully enrolled and completed when anticipated; whether preliminary or interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials will be indicative of results that will be generated in future clinical trials; whether\u202fpegcetacoplan\u202fwill successfully advance through the clinical trial process on a timely basis, or at all; whether the results of the company\u2019s clinical trials will warrant regulatory submissions and whether\u202fpegcetacoplan\u202fwill receive approval from the FDA or equivalent foreign regulatory agencies for GA, PNH, CAD, C3G, IC-MPGN, ALS or any other indication when expected or at all; whether, if Apellis\u2019 products receive approval, they will be successfully distributed and marketed; and other factors discussed in the \u201cRisk Factors\u201d section of Apellis\u2019 Quarterly Report on Form 10-Q filed with the\u202fSecurities and Exchange Commission\u202fon November 2, 2020\u202fand the risks described in other filings that Apellis may make with the\u202fSecurities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.\u202f\u00a0<\/p>\n<p>\n        <strong>Media\u202fContact:<\/strong>\u00a0<br \/>Mark Dole\u00a0<br \/>media@apellis.com\u00a0<br \/>+1\u202f617\u202f997 3484\u00a0<\/p>\n<p>\n        <strong>Investor\u202fContact:<\/strong>\u00a0<br \/>Argot Partners\u00a0<br \/>apellis@argotpartners.com<br \/>+1\u202f212\u202f600 1902\u00a0<\/p>\n<p>\n        <sup>1\u00a0<\/sup>Weber, BHF, Issa, PC, et al. The Role of the Complement System in Age-Related Macular Degeneration.\u00a0\u00a0<br \/>Dtsch\u00a0Arztebl\u00a0Int 2014; 111(8): 133\u20138.\u00a0\u00a0<br \/><sup>2<\/sup>\u00a0Heesterbeek, TJ,\u00a0Lechanteur\u00a0YTE, et al. Complement activation levels are related to disease stage in AMD. Invest\u00a0Ophthalmol\u00a0Vis Sci. 2020;61(3):18.\u00a0\u00a0<br \/><sup>3<\/sup>\u00a0Rudnicka AR, Jarrar Z, Wormald R, et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology\u00a02012;119:571\u2013580.\u00a0<br \/><sup>4<\/sup>\u00a0Wong WL,\u00a0Su\u00a0X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014;2:e106\u2013116.\u00a0<br \/><sup>5<\/sup>\u00a0Seddon, JM, Rosner, B. Validated prediction models for macular degeneration progression and predictors of visual acuity loss identify high-risk individuals. Am J\u00a0Ophthalmol\u00a02019;198:223\u2013261.\u202f\u00a0<br \/><sup>6<\/sup>\u00a0Yates, JRW, Sepp T, et al. Complement C3 Variant and the Risk of Age-Related Macular Degeneration. N Engl J Med 2007; 357.\u00a0<br \/><sup>7<\/sup>\u00a0Weber, BHF, Issa, PC, et al. The Role of the Complement System in Age-Related Macular Degeneration.\u202fDtsch\u00a0Arztebl\u00a0Int 2014; 111(8): 133\u20138.\u202f<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM5MyMzODI1MTY2IzIwMjAwMjY=\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Verana Health a nalysis of American Academy of Ophthalmology IRIS \u00ae Registry presented in a late-breaking oral session Real-world clinical data show significant disease progression over a two-year period in more than 69,000 patients with GA, highlighting the urgent need for treatment Patients were nearly three times more likely to develop new onset\u00a0 wet age-related macular degeneration ( AMD ) in an eye with GA when wet AMD had already been detected in the contralateral eye WALTHAM, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced findings from the largest retrospective database study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The analysis &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380952","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Verana Health a nalysis of American Academy of Ophthalmology IRIS \u00ae Registry presented in a late-breaking oral session Real-world clinical data show significant disease progression over a two-year period in more than 69,000 patients with GA, highlighting the urgent need for treatment Patients were nearly three times more likely to develop new onset\u00a0 wet age-related macular degeneration ( AMD ) in an eye with GA when wet AMD had already been detected in the contralateral eye WALTHAM, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced findings from the largest retrospective database study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The analysis &hellip; Continue reading &quot;Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-13T15:43:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM5MyMzODI1MTY2IzIwMjAwMjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual\",\"datePublished\":\"2020-11-13T15:43:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\\\/\"},\"wordCount\":1575,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTM5MyMzODI1MTY2IzIwMjAwMjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\\\/\",\"name\":\"Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTM5MyMzODI1MTY2IzIwMjAwMjY=\",\"datePublished\":\"2020-11-13T15:43:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTM5MyMzODI1MTY2IzIwMjAwMjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTM5MyMzODI1MTY2IzIwMjAwMjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/","og_locale":"en_US","og_type":"article","og_title":"Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual - Market Newsdesk","og_description":"Verana Health a nalysis of American Academy of Ophthalmology IRIS \u00ae Registry presented in a late-breaking oral session Real-world clinical data show significant disease progression over a two-year period in more than 69,000 patients with GA, highlighting the urgent need for treatment Patients were nearly three times more likely to develop new onset\u00a0 wet age-related macular degeneration ( AMD ) in an eye with GA when wet AMD had already been detected in the contralateral eye WALTHAM, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced findings from the largest retrospective database study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The analysis &hellip; Continue reading \"Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-13T15:43:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM5MyMzODI1MTY2IzIwMjAwMjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual","datePublished":"2020-11-13T15:43:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/"},"wordCount":1575,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM5MyMzODI1MTY2IzIwMjAwMjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/","name":"Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM5MyMzODI1MTY2IzIwMjAwMjY=","datePublished":"2020-11-13T15:43:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM5MyMzODI1MTY2IzIwMjAwMjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTM5MyMzODI1MTY2IzIwMjAwMjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-ga-at-aao-2020-virtual\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380952"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380952\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}